CANCERS BRONCHIQUES NON A PETITES CELLULES NON METASTATIQUES NON RESECABLES
CHIMIOTHÉRAPIE D’INDUCTION AVANT IRRADIATION


Précédent Retour au menu principal  Suivant


Référence

traitement

n pts

RO

(%)

SM

(mois)

survie à 2 ans

p

Mattson,

1988

1. CPA-ADR-CDDP(2x) puis RT (55Gy)

76

49

ND

ND

S

2. RT (55Gy)

78

44

ND

ND

             

Dillman,

1990

1. CDDP-VBL(2x) puis RT (60Gy)

78

46

13,8

26%

S

2. RT (60Gy)

77

35

9,7

13%

             

Morton,

1991

1. MTX-ADR-CPA-CCNU(2x) puis RT (60 Gy)

56

55

10,6

21%

NS

2. RT (60 Gy)

58

64

10,4

16%

             

Le Chevalier, 1991

1. VDS-CPA-CDDP-CCNU(3x) puis RT (65 Gy)

176

31

12

21%

S

2. RT (65 Gy)

177

35

10

14%

             

Gregor,

1993

1. CDDP-VDS(2x) puis RT (50 Gy)

39

62

12,1

ND

NS

2. RT (50 Gy)

39

42

12,4

ND

             

Crino,

1993

1. CDDP-VP16(3x) puis RT (56 Gy)

29

53

12,1

28%

NS

2. RT (56 Gy)

32

32

8,4

14%

             

Wolf,

1997

1. Ifo-VDS (2x) puis RT (50 Gy)

37

57

13,7

24 %

S

2. RT (50 Gy)

41

41

9

12 %

             

Sause,

1995

1. CDDP-VBL (2x) puis RT (60 Gy)

164

 

13,8

ND

S

2. RT (60 Gy)

163

 

11.4

ND

3. RT bifractionnée (69.6 Gy)

163

 

12,3

ND

             

Planting,

1996

1. CDDP-VDS (2x) puis RT (55Gy)+ 1 cure CT

37

41

12,0

 

NS

2. RT (55 Gy)

33

55

12,0

 
             

Brodin,

1996

1. CDDP-VP16 (2x) puis RT (56 Gy)

163

26

11

21%

NS

2. RT (56 Gy)

164

25

10,5

17%

             

Cullen,

1999

I. MMC-Ifo-CDDP

223

54

12

 

NS

RT

223

 

10

 
             

Mattson,

2003

I. Docetaxel (x3) puis RT

134

28

14,8

 

NS

II. RT

140

 

12,6

 
             

Belani,

2005

Carbo (AUC 6) + paclitaxel (225) 2 x puis

       

0,28

I. RT 64 Gy (2 Gy/j)

59

22 %

14,9 m

24 %

II. HART 57,6 Gy (1,5 Gy 3x/j pdt 2,5 sem)

60

25 %

20,3 m

33 %

Beslija,

2005

I. Cisplatine + gemcitabine puis RT (63 Gy)

30

47 %

12,5 m

 

0,067

II. RT (63 Gy)

30

27 %

10 m

 


Références

(1) Mattson K, Holsti LR, Holsti P, Jakobsson M, Kajanti M, Liippo K et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24(3):477-482.

(2) Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323(14):940-945.

(3) Dillman RO, Herndon J, Seagren SL, Eaton WLJ, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88(17):1210-1215.

(4) Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991; 115(9):681-686.

(5) Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83(6):417-423.

(6) Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d'Etude et de Traitement des Cancers Bronchiques). Cancer 1995; 76(5):779-786.

(7) Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy and chemotherapy in localized inoperable non-small- cell lung cancer: a randomized trial. J Natl Cancer Inst 1993; 85(12):997-999.

(8) Crino L, Latini P, Meacci M, Corgna E, Maranzano E, Darwish S et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4(10):847-851.

(9) Wolf M, Hans K, Becker H, Hassler R, von Bultzingslowen F, Goerg R et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 1994; 21(3 Suppl 4):42-47.

(10) Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87(3):198-205.

(11) Sause W, Kolesar P, Taylor S, IV, Johnson D, Livingston R, Komaki R et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117(2):358-364.

(12) Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996; 7(2):139-144.

(13) Brodin O, Nou E, Mercke C, Linden CJ, Lundstrom R, Arwidi A et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer 1996; 32A(11):1893-1900.

(14) Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. J Clin Oncol 1999; 17(10):3188-3194.

(15) Mattson KV, Abratt RP, Ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 2003; 14(1):116-122.

(16) Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005; 23(16):3760-3767.

(17) Beslija S, Dizdarevic Z, Lomigoric J, Zutic H, Musanovic M, Mehic B et al. Randomized phase II study of induction chemotherapy with gemcitabine plus cisplatin followed by sequential radiotherapy versus radiotherapy alone in patients with stage III non-small cell lung cancer. Journal of BUON 2005; 10:347-355.


Retour au début de la page